4.4 Review

Future perspectives on swine viral vaccines: where are we headed?

Journal

PORCINE HEALTH MANAGEMENT
Volume 7, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40813-020-00179-7

Keywords

Vaccines; Review; Viruses; pigs

Funding

  1. Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/D/20002173, BBS/E/D/20002174]
  2. BBSRC [BBS/E/D/20002174] Funding Source: UKRI

Ask authors/readers for more resources

The article discusses the history, types, and importance of variolation and pig vaccines in pig production, as well as the continuous innovation and application of vaccine strategies and tools in pigs with the advancement of genomic sequencing and molecular engineering technologies.
Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world's first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available